| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$115.8M | ROE | −21.82% |
| Net Margin | −288.26% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −22.27% |
| Market Cap | $182.0M | Trading Days | 331 |
| 52W High | 5.50 |
| 52W Low | 1.57 |
| % Off High | −33.03% |
| YTD | 52.07% | 1Y | 103.31% |
| Since incept. (ann.) | 55.53% |
Reportable 100%
| Ann. Volatility (1Y) | 78.47% | Ann. Volatility (3Y) | 74.82% |
| Sharpe (1Y) | 1.32 | Sharpe (3Y) | 0.97 |
| Max Drawdown (1Y) | −27.84% | Max Drawdown (3Y) | −29.27% |
| Beta (3Y, vs SPY) | 1.53 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | $184.4M | — |
| CAMP | Camp4 Therapeutics Corp | $177.6M | — |
| IMRX | Immuneering Corp | $186.6M | — |
| VERU | VERU INC. | $189.5M | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $170.7M | 2.8 |
| ANTX | AN2 Therapeutics, Inc. | $169.3M | — |
| INDP | Indaptus Therapeutics, Inc. | $195.9M | — |
| RNA | Atrium Therapeutics, Inc. | $196.5M | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $168.3M | — |
| GLSI | Greenwich LifeSciences, Inc. | $197.4M | — |
| NERV | Minerva Neurosciences, Inc. |
| $199.4M |
| — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $164.7M | — |
